A novel, multiparametric cardiac safety assay using human myocytes

Award Information
Agency:
Department of Health and Human Services
Amount:
$300,000.00
Program:
SBIR
Contract:
1R43AI104067-01A1
Solitcitation Year:
2013
Solicitation Number:
PA10-123
Branch:
N/A
Award Year:
2013
Phase:
Phase I
Agency Tracking Number:
R43AI104067
Solicitation Topic Code:
NIAID
Small Business Information
THERAPYX, INC.
138 FARBER HALL, 3435 MAIN STREET, BUFFALO, NY, 14214
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
145056607
Principal Investigator
 YINGRU LIU
 (716) 829-2528
 yliu@therapyx.org
Business Contact
 THOMAS CONWAY
Phone: (716) 829-2528
Email: thomasc@therapyx.org
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): Genital tract infection with Neisseria gonorrhoeae (gonorrhea) does not induce a state of specific protective immunity and can be acquired repeatedly. Despite public health measures, the disease persists at an unacceptably high frequency; there is no vaccine against it, and resistance even to the latest generations of antibiotics continues to emerge. New findings reveal that N. gonorrhoeae subverts the immune system for its own benefit by eliciting innate responses thatit can survive and by suppressing specific adaptive responses that would eliminate it. This SBIR application seeks to develop a novel strategy utilizing a proprietary product already developed by TherapyX, Inc., for intravaginal application to redirect theimmune response effectively against N. gonorrhoeae. The product will be evaluated in a mouse model of vaginal gonococcal infection that has become accepted as the only currently available animal model. Phase I aims to establish proof-of- principle that the product can induce anti-gonococcal T-cell and antibody responses against the existing infection and accelerate its clearance, and moreover can be recalled to elicit protection against re-infection. The duration of the recall effect, and its ability to afford protection againt different strains of N. gonorrhoeae, will be determined. Successful completion of Phase I will lead to Phase II in which product dosage will be optimized, toxicity will be tested, and cross-protection against a diversity of naturallyoccurring strains of N. gonorrhoeae and long-term efficacy will be evaluated in preparation for clinical trial. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Gonorrhea is the second-most-frequent, notifiable infectious disease in the UnitedStates; the Centers for Disease Control report gt300,000 cases annually and world-wide incidence is estimated at over 60 million new infections per year. No vaccine is available and the emergence of multiple-drug-resistant strains now raises serious concerns over future treatment options. This proposal seeks to develop a novel strategy of immune intervention against gonorrhea, by redirecting the host's immune response to generate effective immunity that eliminates an existing infection and protects againstre-infection.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government